Upon the injection of CCRF-CEM T-cell leukemia or MDAMB-435 breast cancer cells into Rag-2 mice followed by administering a cocktail of MBD-derived peptides of IGFBP-3 from the C-terminal domain a reduction in the burden of cancer within 7 days was observed as demonstrated by reduced splenomegaly, and reduced bone marrow cancer cell burden (Huq et al., 2009). The gene discussed is IGFBP3; the disease is breast carcinoma.